The accuracy by examining the phosphorylated tau (p-tau), amyloid-β (Aβ42) and total tau (T-tau) protein content in CSF has reached 85–90% for diagnosing AD patients (Khan et al. 2020; Blennow and Zetterberg 2018). Here, MAPT is linked to Alzheimer disease.